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Available online 1 June 2016Objective:Wedetermined the effectiveness of the HATCH score in patients with typical atrial ﬂutter (AFl) under-
going cavotricuspid isthmus (CTI) ablation to predict long-term atrial ﬁbrillation (AF).
Methods:Weconducted an observational retrospective single-center cohort study including all patients admitted
to our hospital for a CTI ablation between 1998 and 2010. The patients were divided into four categories: 1) new-
onset AF (no prior AF and AF during follow-up (FU)); 2) old AF (prior AF and no AF during FU); 3) prior and post
AF (AF prior and post CTI ablation); and 4) no AF.
Results: Four hundred and eight patients were included. In patients without prior AF, the hazard ratio (HR) for
new-onset AF during FU was 0.98 (CI 95%: 0.65–1.50; p = 0.95) and 1.00 (CI 95%: 0.57–1.77; p = 0.98) for
HATCH ≥ 2 and HATCH ≥ 3, respectively. In patients with prior AF, the HR for AF was 1.41 (CI 95%: 0.87–2.28;
p= 0.17) and 1.79 (CI 95%: 0.96–3.35; p= 0.06), for HATCH ≥ 2 and HATCH ≥ 3, respectively. Left atrial enlarge-
ment was positively correlated with the occurrence of AF during FU, especially in the subgroup without prior AF,
which had a HR of 2.44 (CI 95%: 1.35–4.40; p = 0.003), a HR of 2.88 (CI 95%: 1.36–6.10; p = 0.006) and a HR of
3.68 (CI 95%: 1.71–7.94; p = 0.001), for slight, moderate and severely dilated left atrial dimension, respectively,
compared with a normal value.
Conclusions: HATCH score did not predict AF in patients with typical AFl who underwent CTI ablation. Basal left
atrium dimension could help predict new-onset AF.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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CHA2DS2VASc1. Introduction
Atrial ﬁbrillation (AF) occurrence in patients with typical atrial ﬂut-
ter (AFl) who undergo cavotricuspid isthmus (CTI) ablation is common
during follow-updespite antiarrhythmic drug (AAD) treatment, and the
occurrence of AF may be favored by similar electrophysiologic triggers
and substrates [1–5]. AF is a progressive arrhythmia and the risk of pro-
gression is quantiﬁed by the HATCH score, which includes factors of un-
derlying heart disease rather than characteristics of the arrhythmia [6].
The development of AF after successful ablation of typical AFl could be a
result of disease progression precipitated by advanced age andTI, cavotricuspid isthmus; AAD,
epartment, Travesía Choupana
Seara).
land Ltd. This is an open access articlcomorbidities. Therefore, theHATCH scoremay be able to predict AF es-
pecially in isolated AFl patients. This would be clinically relevant for the
anticoagulation therapy strategy after CTI ablation.We have already de-
scribed that chronic obstructive pulmonary disease (COPD) andprior AF
were the main predictors to transition to AF after CTI ablation [7]. This
study aimed to investigate the value of the HATCH score for predicting
AF development in this population.
2. Material and methods
2.1. Study designs
We conducted an observational retrospective single-centre cohort
study including all patients admitted to our hospital for a CTI ablation
for typical AFl between 1998 and 2010. We assessed whether the
HATCH score (hypertension; age N75 years; transient ischemic attack
or stroke; COPD; and heart failure) would be predictive of new-onsete under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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except for stroke and heart failure, which have values of 2 points each.
2.2. Patients
Four hundred and eight consecutive patients with typical AFl who
successfully underwent radiofrequency catheter ablation were includ-
ed. Patientswith intra-atrial re-entrant tachycardia following reparative
surgery for complex congenital heart disease were excluded, as were
patients who underwent concomitant AF ablation during the same
procedure. Patients were classiﬁed into four groups: 1) new-onset AF
(patients with no prior AF who developed AF during follow-up);
2) old AF (patients with prior AF and without AF during follow-up);
3) prior and post AF (patients with AF prior and post CTI ablation);
and 4) no AF (patients without AF prior to ablation or during follow-up)
(Table 1).
We performed an initial clinical evaluation that included a medical
history, physical examination, 12-lead surface ECG, 24-h ECG monitor-
ing, X-ray examination, blood chemistry tests and two-dimensional
echocardiography with color-ﬂow Doppler measurements for all pa-
tients. The use of medications, including beta-blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers and AAD
was at the discretion of the responsible clinician. The use of antithrom-
botic drugs was determined based on the CHADS2/CHA2DS2VASc risk
score. All the patientswere classiﬁed based on theHATCH score. Left atri-
al dimension (LAD) was measured using the M-mode anteroposterior
linear dimension obtained from the parasternal long-axis view. The
reference limits for LAD were according to recommendations forTable 1
Baseline population characteristics.
New-onset AF (n = 97) Old AF (n =
Age 64.8 ± 10 65.6 ± 10
Sex male (n, %) 83 (85.6) 42 (85.7)
Obesity (n, %) 24 (24.7) 10 (20.4)
Tobacco (n, %) 23 (24.7) 10 (20.4)
Alcohol (n, %) 15 (19.2) 7 (17.5)
Diabetes (n, %) 27 (27.8) 8 (16.3)
Hypertension (n, %) 56 (58.3) 22 (44.9)
Dyslipidemia (n, %) 41 (42.7) 17 (34.7)
Peripheral vascular disease (n, %) 6 (6.2) 1 (2.0)
CKD (n, %) 13 (14.3) 7 (14.6)
Pulmonar HT (n, %) 8 (11.1) 3 (7.5)
No cardiopathy (n, %) 30 (32.6) 20 (40.8)
IHD (n, %) 16 (17.4) 6 (12.2)
Heart failure (n, %) 12 (13.5) 8 (16.3)
COPD (n, %) 31 (32.0) 9 (18.4)
Dilated cardiomyopathy (n, %) 11 (12.5) 4 (8.2)
Prior stroke (n, %) 2 (2.1) 0
Stroke post (n, %) 7 (7.2) 2 (4.1)
HATCH 1.35 ± 1.23 1.18 ± 1.09
Persistent AFl, n (%) 47 (53.4) 20 (40.8)
AAD prior
– No
– Amiodarone
– Flecainide
– Propafenone
50 (63.3)
23 (29.1)
6 (7.6)
0
14 (31.1)
21 (46.7)
10 (22.2)
0
AAD post
– No
– Amiodarone
– Flecainide
– Propafenone
84 (86.6)
11 (11.3)
2 (2.1)
0
29 (59.2)
15 (30.6)
5 (10.2)
0
OAC, n (%) 60 (61.9) 36 (73.5)
RAAS i, n (%) 26 (40.7) 13 (38.2)
Statins, n (%) 23 (34.8) 13 (37.1)
Betablockers, n (%) 16 (25.0) 12 (33.3)
LVEF, n (%) 53.7 ± 14.3 49.7 ± 14.5
Exitus, n (%) 23 (23.7) 7 (14.3)
Continuous variables expressed as mean ± SD. Categorical variables expressed as number, pe
COPD: chronic obstructive pulmonar disease. AAD: antiarrythmic drug; OAC: oral anticoagulati
fraction.echocardiographic chamber quantiﬁcation by the American Society of
Echocardiography and the European Association of Echocardiography:
women: mildly abnormal (3.9–4.2 cm), moderately abnormal: 4.3–
4.6 cm, and severely abnormal: ≥4.7 cm; and men: mildly abnormal:
4.1–4.6 cm, moderately abnormal: 4.7–5.2 cm, and severely abnormal:
≥5.2 cm [8].
2.3. Electrophysiological study
The electrophysiological procedurewas performed as previously de-
scribed [5]. Brieﬂy, a standard quadripolar catheter (Usci-Bard Inc., MA,
USA) was used to map the bundle of His, a 10-pole catheter (Usci-Bard
Inc.) was used to locate the coronary sinus and a 12-pole Halo XP cath-
eter (Cordis-Webster Inc., CA, USA) was used to record activation in the
anterolateral aspect of the right atrium. An 8-mm-tip catheter was used
for radiofrequency (RF) ablation in 97.9% of patients and an irrigated-tip
catheter was used in the remaining 2.1%. RF was delivered for 60 s at
each location. The maximum power output was 90 W, and the maxi-
mum temperature was 55 °C. CTI-dependence was conﬁrmed by
concealed entrainment if the AFl rhythm was either present at the be-
ginning of the electrophysiological analysis or induced in the laboratory.
If the patient was in sinus rhythm, bidirectional CTI permeability was
determined before ablation.
The objective of the ablation procedurewas to achieve a bidirection-
al conduction block across the CTI. Bidirectional block was determined
by the sequence of electrical activity between the right atrium, bundle
of His and coronary sinus following a 600-ms stimulation in the coro-
nary sinus and in the inferolateral wall of the right atrium. Persistence49) Prior and post AF (n = 75) No AF (n = 187) p
62.0 ± 12 65.2 ± 11 0.14
62 (82.7) 157 (84.0) 0.94
14 (18.7) 55 (29.4) 0.25
14 (18.7) 55 (29.4) 0.29
19 (29.7) 70 (21.1) 0.47
9 (12.0) 41 (21.9) 0.06
35 (47.3) 106 (57.0) 0.22
28 (37.3) 75 (40.5) 0.77
6 (8.0) 9 (4.8) 0.50
7 (9.5) 35 (19.9) 0.20
3 (4.3) 12 (7.7) 0.52
27 (36.0) 52 (28.1) 0.37
13 (17.6) 35 (19.4) 0.71
16 (21.6) 38 (21.2) 0.40
12 (16.0) 44 (23.5) 0.07
10 (13.5) 14 (7.8) 0.43
0 1 (0.5) 0.31
5 (6.7) 3 (1.6) 0.08
1.23 ± 1.27 1.43 ± 1.25 0.31
24 (32.4) 114 (63.7) 0.43
21 (29.6)
42 (59.2)
7 (9.9)
1 (1.4)
126 (78.8)
26 (16.2)
7 (4.4)
1 (0.6)
0.00
43 (57.3)
24 (32.0)
7 (9.3)
1 (1.3)
159 (85)
27 (14.4)
1 (0.3)
0
0.00
52 (71.2) 93 (49.7) 0.00
16 (48.1) 69 (49.0) 0.86
11 (25.6) 48 (33.8) 0.68
13 (30.2) 33 (23.6) 0.62
58.7 ± 14.2 52.7 ± 14.3 0.22
14 (18.7) 31 (16.6) 0.42
rcentage. CKD: chronic kidney disease; HT: hypertension; IHD: ischemic heart diseases;
on; RAAS i: renin–angiotensin–aldosterone system inhibitors. LVEF: left ventricle ejection
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procedure.
2.4. Post-ablation management and follow-up
All patients underwent continuous ECG monitoring for at least 24 h
before hospital discharge. The strategy for anticoagulation therapy was
to maintain anticoagulation treatment for four weeks after the proce-
dure in all patients. Thereafter, anticoagulation therapy was suspended
in isolated AFl and maintained in prior-AF patients, according to the
CHADS2 or CHA2DS2VASc score (as appropriate because patients were
included from 1998 to 2010). The patients returned for a follow-up
visit every 6 months, and 24-h Holter monitoring for assessing asymp-
tomatic arrhythmia episodeswas performed every year. Each time a pa-
tient went to the emergency room or saw his general practitioner, a
report was ﬁled into the patient's electronic history and an ECG record-
ingwas performed. Long-termmaintenance of oral anticoagulant (OAC)
treatment was determined at the discretion of the responsible clinician
depending on the occurrence of AF during the follow-up. The occur-
rence of AF was deﬁned as documentation during ECG or ECG Holter
monitoring of at least 30 s of AF. The strategy for AAD therapy after
CTI ablation was to maintain the treatment in patients with prior AF
andwithdraw the drug in patients with isolated AFl. Long-termmainte-
nance of AAD therapy was at discretion of the responsible clinician.
2.5. Statistical analysis
Continuous data are presented as the mean ± standard deviation.
Categorical variables are expressed as counts and percentages. We
used a t-test if the continuous variables were normally distributed and
a Wilcoxon two-sample test if the continuous variables were not nor-
mally distributed. The chi-squared test was used to compare categorical
variables. Survival data were described using a Kaplan–Meier analysis.
Survival timewas deﬁned as the time from the date of AFl ablation to
the date of AF, as veriﬁed during the follow-up. Differences between
pairs of survival curves were assessed using the log-rank test.
All statistical analyses were performed in R using the survival pack-
age (for ﬁtting parametric Coxmodels). These packages are freely avail-
able at http://cran.r-project.org.
This study was performed in accordance with the Declaration of
Helsinki (1975) and approved by the Ethics Committee of Clinical Inves-
tigation in Galicia. All enrolled patients gave theirwritten informed con-
sent [23].
3. Results
Four hundred and eight patientswith typical AFlwhounderwent CTI
ablation were followed for a mean time of 5.9 ± 3.1 years (range,
1.6–13.5 years). There were 13 patients (3.2%) with AF during follow-
up who underwent pulmonary vein isolation. These patients were in-
cluded in the series. Acute bidirectional CTI block was achieved in all
of the patients.
They were classiﬁed into four groups based on the occurrence of AF
(Table 1). Therewas nodifference in age among the groups. Therewas a
trend to a higher proportion of diabetes in groupswith AF and the prev-
alence of COPD was higher in the new-onset AF group compared with
the others. There was also a trend toward a lower rate of stroke in theTable 2
Left atrial dimensions among the groups.
LA size New AF (N = 97) Old AF (N = 49) Prior and p
Normal 21 (21.6) 21 (42.8) 23 (30.7)
Mild dilatation 47 (48.5) 19 (38.7) 25 (33.3)
Moderate dilatation 15 (15.5) 6 (12.3) 19 (25.3)
Severe dilatation 14 (14.4) 3 (6.1) 8 (10.7)group with no AF (1.6%). There were no differences in the HATCH
score among the groups.
All patients were discharged with at least four weeks on OAC thera-
py or enoxaparin. Patients with old AF (73%), prior and post AF (71%)
and newAF (62%) had a rate of OAC at the endof follow-up thatwas sig-
niﬁcantly higher than patients with no AF (50%).
Before CTI ablation, the number of patients taking AAD treatment
was signiﬁcantly higher between groups with prior AF than in groups
without prior AF. Patients without prior AF were off AAD after CTI abla-
tion. At the end of follow-up, the number of patients taking AAD who
kept taking the therapy was signiﬁcantly higher between groups with
prior AF than in groups without prior AF, with a rate of 14.4% in patients
with new-onset AF (Table 1).
There were no differences in left ventricular ejection fraction be-
tween the groups. However, we found statistically signiﬁcant differ-
ences in the left atrium dimensions (LAD) between the groups with a
rate of normal LAD that more than doubled in the No AF patients
group (48%) compared with the new-onset AF group (22%; p = 0.001;
Table 2).
The Kaplan–Meier curves in Fig. 1a and b illustrate survival freedom
from AF during follow-up according to risk stratiﬁcation by HATCH
score and prior AF. In patients without prior AF andHATCH ≥ 2, the haz-
ard ratio (HR) for developing AF during follow-up was 0.98 (CI 95%:
0.65–1.50; p = 0.95). In patients without prior AF and HATCH ≥ 3, the
HR for developingAFwas 1.00 (CI 95%: 0.57–1.77; p=0.98). In patients
with prior AF andHATCH ≥ 2, theHR for developingAF during follow-up
was 1.41 (CI 95%: 0.87–2.28; p = 0.17). In patients with prior AF and
HATCH ≥ 3, the HR for developing AF was 1.79 (CI 95%: 0.96–3.35;
p = 0.06) (Fig. 2a and b).
The HATCH score did not predict new-onset AF in the follow up pe-
riod, and the rate of AF after 3 years of follow up was 25% in the
HATCH ≥ 2 group and 20% in the HATCH b 2 group (Fig. 1). The results
for new-onset AF were similar using a cut-off value of 3 for the
HATCH score. In patients with prior AF who developed AF during
follow-up, the rate of AF was higher in the HATCH ≥ 2 group (64%)
than in the HATCH b 2 group (44%) at the 3-year follow-up visit. In ad-
dition, the differencewas higher using a cut-off value of 3 for theHATCH
score, with an AF rate of 75% in patients with HATCH ≥ 3, which was
higher than the 46% rate of AF in patients with HATCH b 3 at the 3
year follow-up visit. However, these differences were not statistically
signiﬁcant. Most of the AF occurrence was noted near the beginning of
the follow-up, with an AF rate of 53% during the ﬁrst year (Fig. 2b).
Fig. 3 shows the AF occurrence in each HATCH category among the
groups.
Patients on AAD treatment prior CTI ablation and at the end of the
study, among the different HATCH categories, are depicted in Fig. 4.
There were no signiﬁcant differences among the HATCH categories in
the percentage of patients on AAD not only in the whole population
but in the isolated typical AFl group.
There was a positive correlation between LAD and AF occurrence
during follow-up. Only 22% of patients with new AF and 31% of patients
with prior and post AF had a normal basal LAD. On the other hand, 52%
of patients with noAF during follow-up had a LA enlargement (Table 2).
The Kaplan–Meier survival curve for the occurrence of AFduring follow-
up among different LAD values is shown in Fig. 5. Multivariate Cox anal-
ysis shows an HR of 1.64 (CI 95%: 1.09–2.47; p = 0.02); 2.31 (CI 95%:
1.43–3.74; p= 0.01); and 2.65 (CI 95%: 1.54–4.55; p= 0.00), for slight,ost AF (N = 75) No AF (N = 187) Total (N = 408) p
89 (47.6) 154 (37.7) p = 0.001
71 (38.0) 162 (39.7)
19 (10.1) 59 (14.5)
8 (4.3) 33 (8.1)
Fig. 1. a. AF freedom cumulative survival curve in isolated AFl patients and HATCH 2. b. AF freedom cumulative survival curve in isolated AFl patients and HATCH 3.
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normal LAD. The Kaplan–Meier curves in Fig. 6a and b illustrate survival
freedom from AF during follow-up based on risk stratiﬁcation for LAD
and prior AF. In patients without prior AF, theHR for developing AF dur-
ing follow-up was 2.44 (CI 95%: 1.35–4.40; p = 0.003); 2.88 (CI 95%:
1.36–6.10; p = 0.006) and 3.68 (CI 95%: 1.71–7.94; p = 0.001) for
slight, moderate and severely dilated LAD, respectively, compared
with normal LAD. In patients with prior AF, the HR for developing AF
during follow-up was 1.06 (CI 95%: 0.59–1.89; p = 0.84); 1.43 (CI
95%: 0.77–2.68; p = 0.26) and 1.65 (CI 95%: 0.75–3.54; p = 0.21) for
slight, moderate and severely dilated LAD, respectively, compared
with normal LAD.
4. Discussion
In our cohort of patients with typical AFl who underwent CTI abla-
tion, the HATCH score was not effective to predict new-onset AF. TheFig. 2. a. AF freedom cumulative survival curve in AF prior patients and HATCH 2HATCH score performance was slightly better when considering only
the group of patients with prior AF.
In a recent report [9], the HATCH score was a good predictor of new-
onset AF after typical isolated AFl ablation, with an area under the curve
of 0.74. However, we did not ﬁnd it to be a reliable predictor for detect-
ing new-onset AF at any of the HATCH score cut-off values. There may
be several reasons for such a difference.
First, in Chen's report [9], the age of patients who developed AF was
65 years, which was signiﬁcantly higher than the age of patients who
did not developAF (61 years). Other studies [5,10–11] did notﬁnd a sta-
tistically signiﬁcant difference in the occurrence of AF related to age, and
in two reports [12–13], patients who developed AF during follow-up
were signiﬁcantly younger than patients who did not develop AF (HR
of 1.46 for those b 65 years of age). In our series, patientswhodeveloped
AF during follow-upwere also younger than patientswhodid not. These
data suggest that ﬁbrosis related to age is not a determining factor in the
occurrence of AF after typical AFl ablation in most studies.. b. AF freedom cumulative survival curve in AF prior patients and HATCH 3.
Fig. 4. Patients on AAD prior CTI ablation and at the end of the study (%).
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tients with HATCH ≥ 2was high (70%).We had amuch lower frequency
of heart failure (50%) and in one-third of patients, the systolic dysfunc-
tion was reversible [2].
Third, in this report [9], the frequency of prior cerebrovascular dis-
ease was signiﬁcantly higher in HATCH ≥ 2 patients than in HATCH b 2
patients (19% vs. 2%). However, the frequency of hypertension was sig-
niﬁcantly lower in HATCH ≥ 2 patients than in HATCH b 2 patients (58%
vs. 70%). AF-related strokes are responsible for about one-third of all is-
chemic strokes [21], but this population consisted of isolated AFl cases
and was, therefore, free from AF. On the other hand, hypertension is
the main risk factor for having an ischemic stroke that is not related to
AF. What, then, was the mechanism of prior stroke in the HATCH ≥ 2
population? Taking into account the difﬁculty in using clinical manifes-
tations to accurately identify AF and AFl prior to ablation, it is possible
that the prior AF patients were under-recognized in this series. In our
series, the frequency of prior cerebrovascular disease was 2% in
HATCH ≥ 2 patients including patients with prior AF. Taken together,
this population [9] seems to be sicker than those in previously reported
studies [5,10–13].
Fourth, AAD treatment during the follow-up was also different
between our series (AAD allowed and under clinician criteria after CTI
ablation) and Chen's report (AAD off after CTI ablation). However, in
our series, the rate of withdrawal during follow-up was high with only
40% of patients with prior AF on AAD treatment at the end of the
study and only 13% of patients among the new-onset AF group. The
main reason for AAD withdrawal was the lack of efﬁcacy. In a previous
short-term follow-up study (16 months), including patients with
AAD-related AFl who underwent CTI ablation, the rate of cessation of
AAD was 25% and the change of AAD due to lack of efﬁcacy was 33%
[24]. In another study Anastasio et al., reported a rate of AF recurrence
as high as 90% in a 5 year follow-up study with all patients on AAD at
the end of the study. [25] Therefore the effect of AAD in preventing AF
after CTI ablation for typical AFl is modest. Anyhow, we did not ﬁnd
any differences in AAD treated patients at the end of study among the
HATCH categories either in the whole population or in isolated typical
AFl group.
AF is a progressive arrhythmia and its progression is driven by un-
derlying heart disease, which is described well by the HATCH score.
An increasing HATCH score indicates a signiﬁcantly higher proportion
of patients in whom AF progressed to a long-lasting form [6]. This fact
could explainwhy theHATCH score had a slightly better prediction abil-
ity between patients who had prior AF.
Enlargement of LA was correlated with occurrence of AF during
follow-up and it reﬂects the structural remodeling of LA [14–15]. It is
a consistent factor of AF occurrence after CTI in most of the series [3,9,
11–12] although a lack of correlation has also been reported [10].
However, more than half of the patients with no AF during follow-upFig. 3. AF during follow-up based on HATCH category.had a dilated LA, and 43% of patients with prior AF that did not develop
AF during follow-up had normal LA dimensions. In addition, LAD corre-
lation was especially observed in patients without prior AF and when
the patients had prior AF, this correlation disappeared. The occurrence
of prior AF is likely the strongest factor for predicting AF after CTI abla-
tion because it gathers electrical and structural remodeling factors and
attenuates the predictive ability for structural factors such as LAD or
HATCH factors alone [7].
Thus, it may seem necessary an electrical remodeling to occur along
with structural remodeling for AF to develop in typical AFl patients who
undergo CTI [16]. This interaction between AF and AFl has long been
studied [17,18]. Recently a clinical study has proposed the AF ablation
strategy in patientswith isolated AFl on top to CTI ablationwith a signif-
icant reduction of new-onset AF assessed by a continuous implantable
cardiac monitor [19]. The HATCH score likely failed to identify patients
with isolated AFl who develop new-onset AF because it takes into ac-
count only structural factors of underlying heart disease progression
and COPD but it does not consider the arrhythmic substrate [20].
When theHATCH score is applied to prior AF patients (considering elec-
trical remodeling), the ability of the score to predict AF improves. Re-
cently, it was shown that AF inducibility after CTI ablation for typical
AFl was a predictive factor of AF occurrence in patients with isolated
AFl, but not in prior AF patients [22]. It is necessary to identify structural
factors that should include LAD and electrical factors that could express
atrial electrical vulnerability (such as AF inducibility), to improve theFig. 5. AF freedom cumulative survival curves and left atrial dimension.
Fig. 6. a. AF freedom cumulative survival curves and left atrial dimension in patients without prior AF. b. AF freedom cumulative survival curves and left atrial dimension in patients with
prior AF.
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dergoing CTI. This will help with the difﬁcult issue of long-term
anticoagulation therapy in this population.
4.1. Limitations
Our study represents a single center's experience. The exact inci-
dence of arrhythmia episodes, especially those thatwere asymptomatic,
is not known and it is difﬁcult to estimate. The retrospective nature of
the study constitutes another limitation and data should be analyzed
with caution.
5. Conclusions
The HATCH score failed to predict new onset AF in patients with iso-
lated typical AFl who are undergoing CTI ablation. Basal LAD could help
predict new-onset AF after CTI ablation.
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